Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22124443 | 0.84 | TACR3 (0.36) | POLB | |
| SCHEMBL15447564 | 0.83 | CHRNB2 (0.43) | KDM1A | |
| SCHEMBL31348898 | 0.81 | ITGB3 (0.43) | POLB | |
| Hydrochloric Acid SCHEMBL17641164 | 0.81 | CHRNB2 (0.42) | KDM1A | |
| SCHEMBL13861304 | 0.81 | POLB (0.48) | KDM1ANAMPTPOLB | |
| SCHEMBL16192179 | 0.79 | NPY5R (0.30) | — | |
| SCHEMBL8502965 | 0.79 | BRD4 (0.39) | POLB | |
| SCHEMBL5901263 | 0.79 | MTNR1A (0.42) | NAMPT | |
| SCHEMBL25205463 | 0.78 | DPP4 (0.32) | — | |
| SCHEMBL21358504 | 0.76 | DPP4 (0.36) | ARG1KDM1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | ARG1 1941/4885KDM1A 4353/4885NAMPT 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.